Index hide1 According to information from the WHO, Until December 8, 97,618,392 cases of covid 19 infection have been confirmed in the United States.
According to information from the WHO, Until December 8, 97,618,392 cases of covid 19 infection have been confirmed in the United States.
According to the WHO, 1,071,245 deaths have been reported due to covid 19 in the United States.
As of December 2, 2022, 647,345,101 doses of vaccine have been administered in the United States.
The Food and Drug Administration (FDA) has approved early in the day the use of bivalent vaccines against the covid 19 virus in 6-month-old babies.
According to the official statement from the FDA, the bivalent (updated) vaccines that have received the agency’s approval are those belonging to the Pfizer and Moderna laboratories. The FDA authorization allows the use of Moderna’s bivalent vaccine as a booster in infants 6 months of age to children 5 years of age, two months after their initial vaccination.
While the updated Pfizer/BioNTech vaccine can now be given as a third dose to children 6 months to 4 years of age who have not completed their primary vaccination series or who have not yet received the third dose.
“More children now have the opportunity to upgrade their protection against COVID-19 with a bivalent COVID-19 vaccine, and we encourage parents and caregivers of those who qualify to consider vaccinating them – especially as we approach to the holidays and winter months, when more time will be spent indoors,” said FDA Commissioner Dr. Robert M. Califf.
Children who completed their initial three-dose vaccination with Pfizer’s original shot are not yet eligible to receive the bivalent booster, the agency said.
The regulator added that data supporting the use of the Pfizer/BioNTech bivalent injection as a booster in this age group is expected in January.
Vaccines for the youngest children in the United States were only approved in June of this year, making them the latest group to be eligible for vaccination.
Government data shows that only 2.7% of children under two years of age and less than 5% of children two to four years of age who are eligible have completed their primary vaccination series as of November 30, representing an acceptance slowing of initial doses of the vaccine in young children.
The Moderna vaccine for children under 6 years of age is a two-dose, 25-microgram vaccine, with the injections given approximately four weeks apart. The Pfizer/BioNTech vaccine for younger children is a lower dose regimen of 3 injections given for at least 11 weeks.